Clearpoint Neuro Inc
NASDAQ:CLPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Clearpoint Neuro Inc
NASDAQ:CLPT
|
US |
|
V
|
Volkswagen AG
XMUN:VOW3
|
DE |
|
A
|
Astro Resources NL
ASX:ARO
|
AU |
|
V
|
Vicostone JSC
VN:VCS
|
VN |
Clearpoint Neuro Inc
Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The company is headquartered in Solana Beach, California and currently employs 80 full-time employees. The company went IPO on 2019-07-03. The Company’s product platforms include SmartFlow Cannula and ClearPoint Navigation System Software. The SmartFlow Cannula is being utilized in approved combination product clinical and preclinical studies by pharmaceutical companies and academic research customers for various research and clinical trials in connection with delivery of therapeutic agents. The ClearPoint Navigation System Software is a software for surgical planning, navigation to target, and device delivery. The Company’s software and MRI-compatible workstation coordinate with the scanner to effectively utilize intraprocedural MR images. This provides real-time navigational instruction for the neurosurgeon to reach the desired anatomical target with a high degree of precision.
Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The company is headquartered in Solana Beach, California and currently employs 80 full-time employees. The company went IPO on 2019-07-03. The Company’s product platforms include SmartFlow Cannula and ClearPoint Navigation System Software. The SmartFlow Cannula is being utilized in approved combination product clinical and preclinical studies by pharmaceutical companies and academic research customers for various research and clinical trials in connection with delivery of therapeutic agents. The ClearPoint Navigation System Software is a software for surgical planning, navigation to target, and device delivery. The Company’s software and MRI-compatible workstation coordinate with the scanner to effectively utilize intraprocedural MR images. This provides real-time navigational instruction for the neurosurgeon to reach the desired anatomical target with a high degree of precision.
Revenue: Full-year 2025 revenue was $37.0 million, up from $31.4 million in 2024; Q4 revenue was $10.4 million versus $7.8 million a year earlier.
Guidance: Management expects 2026 revenue of $52 million to $56 million, which excludes meaningful commercial drug-delivery revenue and reflects recent FDA communications and IRRAS integration priorities.
Growth Drivers: Company expects double-digit growth across four product pillars in 2026 (biologics & drug delivery, navigation & robotics, laser & access, neurocritical management) and sees material upside if neuro gene therapies get commercial approvals.
Acquisition: IRRAS acquisition closed November 20, 2025; contributed $1.2 million of 2025 revenue and brought the IRRAflow product line into the Navigation/Therapy segment.
Profitability & Cash: Gross margin ~61% for the year (62% in Q4); operating cash used $23.9 million in 2025; cash and cash equivalents $45.9 million at year-end after $51.4 million net proceeds from notes/stock financings.
Clinical momentum: More than 60 active biopharma partners, 25+ active clinical trials, and 10+ partner programs in some form of FDA expedited review — management highlights Parkinson's and drug-resistant epilepsy among the largest indication opportunities.
Near-term milestones: Clearing/rollout of ClearPoint 3.x software (CE marked), PRISM clinical publication planned this year, GLP capability ramp at the ClearPoint Advanced Laboratories (CAL), and ARCH randomized trial readout (IRRAflow) expected later this year.
